Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesAddition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesFailure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.The STAMPEDE trial: paradigm-changing data through innovative trial design.Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted".Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate CancerMortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes.Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy.Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.Contemporary management of men with high-risk localized prostate cancer in the United States.The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer.Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.The very-high-risk prostate cancer: a contemporary update.A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.[Treatment mapping of prostate cancer in DVPZ prostate centers in Germany].Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer.Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination.Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.Drug development for noncastrate prostate cancer in a changed therapeutic landscape.[Radiation therapy of locally advanced prostate cancer].[When is a nonsurgical approach possible for metastatic primary tumors and lymph node metastases of the urinary bladder and prostate?]Reply to being a widower may be an indication for routine prostate-specific antigen screening above age 69 years, which the American Urological Association recommends as a cutoff point.Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.[Multimodal therapy of locally advanced prostate cancer].Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity.[Radiotherapy in node-positive prostate cancer].Prostate cancer: 'The prostate' in patients with metastatic prostate cancer: to treat or not to treat?
P2860
Q26744606-885BEF0B-278D-4C6F-AB06-778C37CCAD5BQ26771537-02380ED5-7A1D-460E-B8B5-3D8C0671F39AQ28067404-90A008C5-26E9-4A6B-B691-4366AB9DEE81Q31028126-16E5FBF9-000E-4D1E-9D44-DEE0D4976E12Q36009462-6C2C8271-6525-48FB-8F18-DAB39D6B5AC5Q36163344-83018DFB-E6F4-4B69-9AB9-7CC32055ED74Q36241918-72F70F89-0553-4D38-B63B-C580E7AB1A97Q36474222-E8DF0F16-BB14-4F94-AC73-B3F0B99F46E1Q36970812-94003281-8DD8-4AF8-A4A6-A4BEEB2B0EBCQ37339657-F907D55F-A3D4-4402-BA31-22E98A94B575Q37621409-71A0AAF2-EA52-409B-B7EA-0FD81DECCEEAQ37708169-4C4FDB66-79C6-4F0A-9817-F25BAC619A88Q37708171-176B38CC-C9F1-475E-860F-9EC64320EB83Q37735433-795E6917-4D9E-46ED-A962-8E03D5893DDBQ38399316-84F2300A-2C2E-44FC-BBAB-2DC182CF7071Q38519540-6D2CD311-1650-4CC5-97E9-444C99AE4709Q38603110-A6727B56-C7BE-4BF6-8BA7-422AF6C0AD37Q38717765-FC723F9C-D385-4015-82C9-7EA46BAE66CAQ38721090-C581B4E3-B652-4FA9-87A3-3B2B83915E29Q38747059-A4293756-7473-43A6-99F8-138FEF252DCEQ38770371-8CA953FC-4A87-4283-8856-B352A2CE0634Q38809389-742931E6-2274-4DAC-896B-B93E6C38459BQ38952181-6E856E38-FC42-4DCB-ADE7-367A57650D6EQ40456879-71FE3EFA-7696-4026-9860-0F35B291CEAAQ40584866-86ECBA5A-3E8A-440C-8292-3397E9795A04Q41167218-6630C428-73B0-41B5-92B9-14E6B14C7534Q41708691-9DEDED65-9987-481A-BA43-436F333A0805Q42380315-5E5162FB-CAC3-41DD-9F44-13C0051017D2Q47708668-C9359430-072B-45BD-87DE-6F209F204F28Q48194820-2D339044-9995-4223-8607-AE974A260B5EQ48276400-EAD2B1EE-3050-4B5F-9D02-4ED29B1A3157Q48629219-899CD241-8F10-4B5F-9DC4-D923120C131AQ49567687-DA481D17-F09C-40AF-A2F5-72B09C3A9800Q50715530-D64B1897-FAEB-4FF9-8E5D-C02D06F1FFB6Q51709571-323C6077-B301-4E6E-8721-EDE52A3D8688Q52660703-6ED64D92-2F64-4C60-9D83-0657EC29607EQ52855360-EECF72B0-A557-4EE9-B4FD-024A06DAB390Q53083102-DA77C140-C951-46E1-92F8-D00953707E6CQ53170919-27D77A48-AEDB-4F17-971C-195CC7E7D8CFQ53835461-B45D2352-63DC-4691-AC01-942E0B20C766
P2860
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@ast
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@en
type
label
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@ast
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@en
prefLabel
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@ast
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@en
P2093
P2860
P50
P356
P1476
Final Report of the Intergroup ...... cally Advanced Prostate Cancer
@en
P2093
Andrea Hiltz
Charles Hayter
Edmund C Kostashuk
Gordana Jovic
Gregory Swanson
James B P Barber
Jinka Sathya
John Anderson
John Hetherington
Luis Souhami
P2860
P304
P356
10.1200/JCO.2014.57.7510
P407
P577
2015-02-17T00:00:00Z